- NEWS
- Update 19 March 2024
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 23, 235-237 (2024)
doi: https://doi.org/10.1038/d41573-024-00051-1
Updates & Corrections
-
Update 19 March 2024: The article has been updated to note that the FDA's accelerated approval of resmetirom did not include a requirement for biopsy diagnosis in the prescribing information and to clarify that the phase III trial designed to provide confirmatory evidence to support full approval is ongoing. The status of the phase III trial of pegozafermin has been clarified, and a phase II trial of the combination of ervogastat and clesacostat has been added to the table.